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Abstract Long noncoding RNA 19 (H19) has been shown to
promote bladder cancer cell proliferation and metastasis.
However, little is known about how miR-675, mature product
of H19, contributes to bladder cancer cell proliferation. In this
study, we first evaluated the expression of miR-675 in bladder
cancer tissues by quantitative real-time PCR (qRT-PCR) and
defined its biological functions by flow cytometry and West-
ern blotting. We found that miR-675 expression levels were
remarkably increased in bladder cancer tissues as compared
with adjacent noncancerous tissues or normal bladder tissue
from health donors; moreover, enhanced miR-675 expression
was also observed in bladder cancer cell lines. Ectopic expres-
sion of H19 significantly increased bladder cancer cell prolif-
eration and miR-675 expression in vitro. Furthermore, over-
expression of miR-675 promoted bladder cancer cell prolifer-
ation, while suppression of miR-675 induced G1 phase cell
cycle arrest and promoted cell apoptosis. Western blotting
analysis further identified that miR-675 inhibited p53 activa-
tion, decreased the ratio of Bax/Bcl-2 and cyclin D1 expres-
sion in bladder cancer cells; those effects may result in the
abnormal proliferation of bladder cancer cells. In conclusion,
abnormal enhanced miR-675 expression increases bladder
cancer growth by regulating p53 activation, and thus may be
helpful in the development of effective treatment strategies for
bladder cancer.
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Introduction
Human bladder cancer was the ninth most common cancer
with an estimated 429,793 new cases and 165,068 deaths reg-
istered in 2012 worldwide [1]. It was three times more com-
mon in men compared with women and ranks sixth among
cancers in men [2]. Bladder cancer comprises distinct histo-
pathological patterns and clinical behaviors and thus making
serious obstruction in the controlling of bladder cancer [3, 4].
The most common histological type of bladder cancer is
urothelial carcinoma, which recurs frequently and the progno-
sis is generally over 85 % survival at 5 years, rarely accom-
pany with muscle invasion, whereas muscle-invasive bladder
cancer frequently progresses to distant life-threatening metas-
tases, with survival rate only about 6 % [5–8]. Therefore,
understanding the molecular mechanisms involved in bladder
cancer growth is critical to the development of identifying
new therapeutic targets for bladder cancer.
Emerging evidence showed that long noncoding RNA 19
(H19) possesses oncogenic properties and is the key regulator
in carcinogenesis and metastasis of bladder cancer [9–14].
Upregulated H19 promoted the proliferation and metastasis
of bladder cancer cells [10, 9]. Furthermore, H19 RNA level
was greatly enhanced in tumor of human bladder cancer cells
formed in nude mice and in patients with bladder cancer [11,
12]; it also could serve as a prognostic tumor marker for the
early recurrence of bladder cancer [14, 13].
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The molecular mechanisms are involved in H19-induced
tumor cell proliferation including two aspect: (1) Berteaux
et al. demonstrated that H19 RNA was actively linked to
E2F1 and thus promote cell cycle progression of breast cancer
cells [15]. Furthermore, H19 also has been found to promote
cancer cell proliferation by directly inactivating tumor sup-
pressor p53 and increasing ID2 expression [9, 16]. (2) H19
functioned in an indirect way to promote tumor cell prolifer-
ation. As the mature product of H19, H19-derived miR-675
regulated tumor cell proliferation through downregulation of
its targets, tumor suppressor retinoblastoma (RB) [17], and
Runt-related transcription factor 1 (RUNX1) [18]. Particular-
ly, RUNX1 stimulates tumor suppressor p53 protein in re-
sponse to DNA damage [19–21].
The H19/miR-675 signaling axis has been found to pro-
mote progression of different cancers, including colorectal
cancer [17], gastric cancer [18], glioma [22], and prostate
cancer [23]. However, little is known about whether H19-
derived miR-675 regulates bladder cancer proliferation. Thus,
in this study, we evaluated the possible regulatory role of H19-
derived miR-675 in bladder cancer cell proliferation.We dem-
onstrated that miR-675 expression level was remarkably in-
creased in patients with bladder cancer and bladder cancer cell
lines. Furthermore, overexpression of miR-675 markedly in-
creased bladder cancer cell proliferation, whereas miR-675
inhibitor treatment promoted apoptosis and induced G1 phase
cell cycle arrest in human bladder cancer cells. Molecular
analysis further confirmed that miR-675 downregulated p53
expression, and may thus inhibited p53-mediated cell cycle
arrest and apoptosis.
Materials and methods
Tissue samples and cell lines
Human bladder tissues were obtained with informed con-
sent from Jiangsu Province Official Hospital, First Affili-
ated Hospital of Nanjing Medical University. The proto-
cols used in the study were approved by the Hospital’s
Protection of Human Subjects Committee. Forty-eight
pathologically diagnosed biopsy specimens and adjacent
normal tissues were acquired from patients with bladder
cancers. The patients’ characteristics are detailed in Table 1.
Five cases of normal bladder tissues were obtained from
patients without bladder cancer (including patients with
benign prostatic hyperplasia). Normal urothelial cells were
collected as previously described [24, 25]. Human bladder
cancer cells (RT4, HT-1376, 5637, 253J, TCCSUP, T24,
and J82) were obtained and maintained as recommended
by American Type Culture Collection (ATCC, Manassas,
VA).
Quantitative real-time PCR
Total RNA was extracted from cancer tissues or cells using
Trizol reagent (Life Technologies, Carlsbad, CA) according to
the manufacturer’s protocol. For miR-675 detection, reverse
transcription (RT) was conducted with Applied Biosystems™
TaqMan® MicroRNA Reverse Transcription Kit (Life Tech-
nologies, Carlsbad, CA). The primers for the miR-675 were
purchased from Life Technologies (4427975, Carlsbad, CA).
U6 was used for normalization. H19 expression was per-
formed as Yan et al. described [22]. The ABI StepOne Plus
(Applied Biosystems, Foster City, CA) was used to perform
the amplification reaction. And, the date was analyzed by the
2−ΔΔCt method. Each experiment was performed in triplicate.
Transfection
To overexpress H19, H19 cDNA (GenBank accession no.
NR_002196.1) was constructed into the multiple cloning sites
of pcDNA3.1 vector (Invitrogen) according to Zhuang et al.
[18, 9]. Knockdown expression of H19 was performed by
transfection with specific siRNA or its negative control
(H19: 4390771, Life technologies, Carlsbad, CA), respective-
ly. A total of 0.5 μg of empty vector or pcDNA-H19 was
transfected into bladder cancer cells by using Lipofectamine
2000 (Invitrogen™, Life Technologies), respectively. miR-
675 mimic, inhibitor, and negative control were purchased
from Life Technologies (Carlsbad, CA). A total of 2×105 cells
Table 1 The characteristics of patients with bladder cancer
Characteristic Cases (%) miR-675a p value
Total 48 3.87±1.52
Gender 0.2608
Male 33 (68.8) 4.05±1.53
Female 15 (31.2) 3.51±1.47
Mean age (years, range) 65 (43-77)
T stage <0.0001
Ta 3 (6.3) 0.71±0.16
T1 13 (27.1) 2.91±1.26
T2 16 (33.3) 3.99±0.63
T3 12 (25.0) 4.78±0.76
T4 4 (8.3) 6.28±0.69
N stage <0.0001
N0N1 35 (72.9) 3.39±1.39
Higher 13 (27.1) 5.21±0.98
Grade <0.0001
1–2 8 (16.7) 1.59±1.26
3 28 (58.3) 3.93±0.89
4 12 (25.0) 5.28±0.97
aMean±SD, relative expression of miR-675 in bladder cancer tissues
compared with adjacent normal tissues
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were plated in 24-well plate for 24 h and then transfected with
15 nM of miR-675 mimic/inhibitor/negative control by using
lipofectamine 2000 (Invitrogen™, Life Technologies) for
48 h. The cells were then subjected to RNA/protein extraction
or further functional assays.
Cell proliferation
Cell proliferation assays were carried out with a Cell Counting
Kit-8 (Beyotime, shanghai, China) [26]. 253J and RT4 blad-
der cancer cells were plated in 24-well plates at approximately
2×105 cells per well. Cells were then transfected with
pcDNA-H19 or H19-siRNA, and the numbers of cells per
well were detected by the absorbance (450 nm) of reduced
WST-8 at the indicated time points. The absorbance
(450 nm)was measured by using SpectraMax® i3xmicroplate
reader (Molecular Devices, Sunnyvale, CA).
Cell apoptosis
Evaluation of bladder cancer cell apoptosis was performed by
using FITC Annexin V Apoptosis Detection Kit with PI
(Biolegend, San Diego, CA). The cells were washed twice
with cold BioLegend’s Cell Staining Buffer, and then resus-
pended cells in Annexin V Binding Buffer at a concentration
of 0.25–1.0×107 cells/ml. This suspension (100 μl) was
stained with 5 μl of FITC Annexin Vand 10 μl of propidium
iodide. Then, gently vortexed the cells and incubated for
15 min at room temperature (25 °C) in the dark. Added
400 μl of Annexin V Binding Buffer to each tube and ana-
lyzed by flow cytometry.
Cell cycle analysis
Bladder cancer cells were trypsinized, fixed in 70% ethanol at
least 30 min at 4 °C. Then, washed with phosphate-buffered
saline (PBS) and incubated in 200 μl PBS containing PI
(50 μg/ml) and RNAse A (20 μg/ml, Sigma) for 30 min at
37 °C. Samples were then analyzed for their DNA content by
BD accuri™ C6.
Western blot
Proteins were extracted from cells with RIPA lysis buffer
(Beyotime, China) and were quantified using a BCA Protein
Assay Kit (Beyotime, China). Whole cell lysates (40 μg of
protein lysates for detecting p53, p21, cyclinD1 and β-actin,
and 80 μg for detecting Bcl2, Bax) were run on 8 or 12 %
SDS-PAGE and then transferred to PVDF membranes
(Millipore, USA). The membrane was blocked in 5 % nonfat
milk and incubated overnight with the specific primary anti-
body at 4 °C, and further incubated for 1 h with the HRP-
conjugated secondary antibody. The immunoreactive bands
were visualized by Immobilon™Western Chemiluminescent
HRP Substrate (ECL) (Millipore, USA), using UVP
Bioimaging system (UVP, Upland, CA).
Statistical analysis
All data are expressed as means±standard deviation (SD)
from at least three separate experiments and analyzed by
Graphpad Prism V.5.00 software (San Diego, CA, USA).
The differences between groups were evaluated by using Stu-
dent’s t test (two-sided) or one-way ANOVA. p<0.05 was
considered statistically significant.
Results
miR-675 expression is significantly upregulated in bladder
cancer
H19 has been shown to promote the proliferation and metas-
tasis of bladder cancer [9, 10], as the derivative of H19, miR-
675 also abnormally enhanced cancer cell proliferation, like
gastric cancer, glioma, and colorectal cancer [22, 17, 18]. In
order to further identify whether miR-675 induces bladder
cancer proliferation, we first examined the expression of
miR-675 in bladder cancer tissues, adjacent normal control
tissues, and normal bladder tissues from patient without blad-
der cancer. As shown in Fig. 1a, the expression of miR-675
was significantly upregulated in most bladder cancer tissues;
however, this increase was not observed in patients without
bladder cancer. Furthermore, increased expression of miR-
675 was also observed in several human bladder cancer cell
lines (RT4, HT-1376, 5637, 253J, TCCSUP, T24, and J82)
(Fig. 1b). Thus, these data indicate that upregulation of miR-
675 may be related to the progression of bladder cancer.
miR-675 promotes bladder cell proliferation in vitro
As a mature product of H19, miR-675 is the pivotal
intermediator that H19 exploited to enhance the carcinogene-
sis and metastasis of different cancers [27, 17, 23]; so, we
further examined the regulatory role of H19 in miR-675 ex-
pression in 253J and RT4 bladder cancer cells. First, the ex-
pression of H19 was interfered or overexpressed in 253J cells,
as shown in Fig. 2a; ectopic expression of H19 (Fig. 2a)
caused a significant upregulation of miR-675 expression
(Fig. 2c) and increased cell proliferation of 253J cells and
RT4 cells (Fig. 2e, f). Furthermore, H19-siRNA treatment
(Fig. 2b) decreased the miR-675 expression level (Fig. 2d)
and inhibited 253J cell proliferation (Fig. 2e, f). So, these data
suggest that H19 promotes cell proliferation and miR-675
expression in bladder cancer.
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Fig. 1 miR-675 levels are upregulated in bladder cancer. a miR-675
expression in bladder cancer tissues, adjacent normal control tissues
(n=48) and tissues from health donors (n=5) were analyzed by qRT-
PCR. Total RNA was extracted and subjected to qRT-PCR to analyze
the CT values of bladder cancer normalized to U6 in each sample. The
normalized value (ΔCt) of bladder cancer tissue or tissue from health
donor was then compared with normal tissue in each group (ΔΔCt). The
results are expressed as 2−ΔΔCt. bmiR-675 levels were evaluated by qRT-
PCR in seven bladder cancer cell lines. Normal urothelial cells were used
as control. Data are presented as mean±SD (n=3)
Fig. 2 H19 promotes cell
proliferation and miR-675 ex-
pression in bladder cancer cells.
253J cells were transiently
transfected with pcDNA-H19 or
H19-siRNA. Forty-eight hours
later, the H19 (a, b) and miR-675
(c, d) expression in H19 knock-
down or overexpressed cells was
validated using qRT-PCR. Cell
proliferation of 253J cells (e) and
RT4 cells (f) were evaluated by
the absorbance (450 nm) of re-
duced WST-8. The absorbance at
450 nm was measured at 12, 24,
48, and 72 h after transfection.
Data are presented as mean±SD
(n=3)
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As H19 has been shown to promote proliferation and me-
tastasis of bladder cancer [9, 10], then we treated 253J cells
with miR-675mimic or inhibitor to verify the role of miR-675
in regulating proliferation of 253J cells and RT4 cells. miR-
675 expression was significantly enhanced or decreased with
the transfection of microRNA into 253J cells (Fig. 3a), and
more importantly, overexpression of miR-675 enhanced cell
proliferation of 253J cells (Fig. 3b) and RT4 cells (Fig. 3c),
while miR-675 inhibitor showed a significant inhibitory role
in cell proliferation. Thus, these data confirm that upregulation
of miR-675 in bladder cancer increases tumor cell growth
in vitro.
miR-675 promotes cell cycle progression and inhibits cell
cycle arrest
To further evaluate whether this miR-675-induced promotion
of cell proliferation was due to inhibit cell cycle arrest and/or
apoptotic death, we first examined the effect of miR-675 on
cell cycle of 253J cells and RT4 cells. As shown in Fig. 4a,
cells in the S phase were significantly increased, and cells in
the G0/G1 phase were significantly decreased by the miR-675
mimic treatment in both these two cell lines. Next, we
assessed whether downregulated expression of miR-675 con-
tributes to cell apoptosis. Figure 4b shows that miR-675 in-
hibitor significantly promoted the apoptosis of bladder cancer
cells. Taken together, these data suggest that miR-675 posi-
tively regulates the proliferation of bladder cancer cells
through cell cycle arrest and apoptosis inhibition.
miR-675 suppresses p53 activation
Compared with miR-675 mimic, miR-675 inhibitor signifi-
cantly induced G0/G1 arrest in 253J cells (Fig. 4a), and more
importantly, it has been well established that tumor suppressor
p53 induces G1 arrest in cells in response to stress [28, 29].
The major downstream effectors of p53 include p21 and
cyclin D1, which mediate G(1)-S phase cell cycle progression
[30, 31]. So, we further detected the expression of p53 in
response to miR-675 treatment. As shown in Fig. 5a, miR-
675 significantly decreased p53 expression, as well as p21;
furthermore, miR-675 enhanced cyclin D1 expression. These
results indicate that miR-675 may promote cell cycle progres-
sion by reducing p53 expression, and thus inhibiting p53-
mediated cell cycle arrest.
Besides p21 and cyclin D1, p53 could also regulate a vari-
ety of target genes involved in apoptosis including Bcl-2 and
Bax [32]. Increase in the ratio of Bax/Bcl-2 is known to initi-
ate apoptosis, in Fig. 5a, b, miR-675 mimic markedly down-
regulated the expression ratio of Bax/Bcl-2, and miR-675 in-
hibitor significantly enhanced the expression ratio of Bax/Bcl-
2. Therefore, these data hint that upregulation of miR-675
expression may inhibit cell apoptosis by regulating p53 acti-
vation in bladder cancer.
Discussion
Currently, emerging evidence has confirmed that the human
long noncoding RNAH19 is upregulated in many cancers and
promotes cancer progression, including bladder cancer [13,
27, 22, 17, 9, 10, 33]. The mechanisms involved in the regu-
latory role of H19 are complex, and mostly associated with its
function as the precursor of miR-675 [22, 17, 23, 18, 27].
However, whether miR-675 involved in H19-mediated pro-
gression of bladder cancer remains unclear. In the present
study, we investigated the involvement of H19-derived miR-
675 and p53 in cell proliferation of bladder cancer. Our results
demonstrated that miR-675 increases bladder cancer cell pro-
liferation by inhibiting cell cycle arrest and apoptosis, and this
effect may be depending on its downregulation of p53
expression.
H19 expression is significantly correlated with tumor grade
and is a marker of early recurrence in bladder cancer [13, 12,
Fig. 3 miR-675 increases bladder cancer cell proliferation. a 253J cells
were transiently transfected with miR-675 mimic or inhibitor. Forty-eight
hours later, the miR-675 expression was validated using real-time RT-
PCR. Cell proliferation of 253J cells (b) and RT4 cells (c) was evaluated
by the absorbance (450 nm) of reduced WST-8. The absorbance at
450 nm was measured at 12, 24, 48, and 72 h after transfection. Data
are presented as mean±SD (n=3)
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9, 10]. As the mature product of H19, our data showed that
miR-675 was expressed at higher levels in bladder cancer
tissues than in adjacent noncancerous tissues. H19 positively
regulated miR-675 expression in bladder cancer cells, and
upregulation of miR-675 significantly promoted cell prolifer-
ation of bladder cancer cells in vitro. To further identify
whether miR-675-induced cell proliferation was due to cell
cycle arrest and/or enhanced apoptosis, 253J and RT4 bladder
cancer cells were transfected with miR-675 mimic or inhibitor
and analyzed by flow cytometry. Our data showed that miR-
675 overexpression in cells significantly reduced G1 arrest
and cell apoptosis. It has been well established that p53 in-
duces G1 arrest in tumor cells; we thus hypothesize that p53
may negatively regulate miR-675 in bladder cancer cells.
Many targets of miR-675 have been proposed in different
tumors, such as Twist1 and RB in hepatocellular carcinoma
and colorectal cancer [34, 17], CALN1 and RUNX1 in gastric
cancer [27, 18], TGFBI in prostate cancer [23]. It should be
noted that RUNX1 is an important upstream activator of p53
and enhances p53 activity in response to DNA damage in
tumor cells [19]. In our chosen cell lines, RT4 and 253J were
p53wild type [35], and the others were p53mutant [36, 37]. In
our results, we found that miR-675 negative regulated the
expression of p53 and its downstream proteins in both 253J
cells and RT4 cells. However, we found that the effects of
miR-675 in RT4 cells were not apparent as in 253J cells; this
may be owned to that 253J was invasive bladder cancer cells,
while RT4 was noninvasive cells [10]; the expressions of
miR-675 and H19 were remarkably lower in RT4 cells.
Zhuang et al. demonstrated that miR-675 inhibited
Fig. 5 miR-675 inhibits p53 and p53-dependent protein expression. 253J
cells were transiently transfected with miR-675 mimic or inhibitor. Forty-
eight hours later, whole cell lysate was used for the Western blotting
analysis. p53, p21, cyclin D1, Bcl-2, Bax, and β-actin were detected with
their respective antibodies (a). Relative expression of Bax and Bcl-2 was
analyzed by gray scale (b),β-actin was used as endogenous control. Data
are presented as mean±SD (n=3)
Fig. 4 Downregulation of miR-675 expression induces bladder cancer
cell apoptosis and G1 phase cell cycle arrest. 253J cells and RT4 cells
were transiently transfected with miR-675 mimic or inhibitor. Forty-eight
hours later, cell cycle arrest (a) and apoptosis (b) were analyzed by flow
cytometry. Data are presented as mean±SD (n=3)
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proliferation of both p53 wild type and mutant gastric cancer
cell lines [18]. In preliminary studies, we have found that miR-
675 induced a G2-M arrest in p53 mutant bladder cancer cells
(data not shown), and next, we will examine the role of miR-
675 involved in proliferation of p53 mutant bladder cancer
cells and explore the detailed molecular mechanisms.
In summary, we demonstrated that miR-675 expression is
markedly increased in bladder cancer tissues and cell lines
compared with normal control. miR-675 was positively regu-
lated by H19, and overexpression of miR-675 increases cell
proliferation of human bladder cancer cells. We further con-
firmed that miR-675 induces a G1 arrest and inhibits cell
apoptosis, and this may depend on its negative regulatory role
for p53 expression. In conclusion, our results suggest an im-
portant role for miR-675 in the molecular etiology of bladder
cancer and highlight potential application of miR-675 in blad-
der cancer therapy.
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